Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910962 | 0.93 | OPRM1 (0.52) | CCR3DRD2OPRM1OPRL1OPRD1 | |
| SCHEMBL10028305 | 0.90 | OPRL1 (0.46) | CCR3OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL9910960 | 0.89 | CCR3 (0.50) | CCR3DRD2OPRM1OPRL1OPRD1 | |
| SCHEMBL5471021 | 0.84 | KMT2A (0.56) | CCR3DRD2OPRM1ADRA1AMEN1 | |
| SCHEMBL14307260 | 0.83 | CCR3 (0.69) | CCR3DRD2OPRM1OPRL1ADRA1A | |
| SCHEMBL10424458 | 0.82 | OPRM1 (0.57) | DRD2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL17888226 | 0.82 | CYP2D6 (0.48) | DRD2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL10287607 | 0.82 | OPRM1 (0.63) | CCR3DRD2OPRM1OPRL1ADRA1A | |
| SCHEMBL12925944 | 0.81 | OPRM1 (0.49) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL15543779 | 0.81 | MAPT (0.55) | CCR3DRD2OPRM1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | claimed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | claimed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| CN-113214102-A | Amine-containing transfection reagents and methods of making and using same | 生命技术公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108358812-B | Amine-containing transfection reagents and methods of making and using same | 生命技术公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| CN-104910025-B | Alkamine lipid and its purposes | 麻省理工学院 | 2019-07-16 | — | — | CN | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| CN-1680418-A | Ketolactones, their use and process for their preparation and pharmaceutical compositions containing them | ABBOTT LAB (US) | 2005-10-12 | — | — | CN | disclosed |
| US-6844333-B1 | Method of treating atherosclerosis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| CN-1271363-A | 3' -N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity | ABBOTT LAB (US) | 2000-10-25 | — | — | CN | disclosed |
| CN-1237183-A | 6-0-substituted ketolides with antibacterial activity | ABBOTT CO (US) | 1999-12-01 | — | — | CN | disclosed |
| CN-1224427-A | 6-O-substituted erythromycin compounds and preparation method thereof | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | disclosed |
| US-4325953-A | 4-Aryl-4-aryloxypiperidines | JOHN WYETH AND BROTHER LIMITED (GB) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | CCR3 17/4885DRD2 2074/4885OPRM1 703/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CCR3 1998/4885DRD2 4607/4885OPRM1 3967/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | CCR3 3530/4885DRD2 3983/4885OPRM1 4575/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | CCR3 4635/4885DRD2 4829/4885OPRM1 4147/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CCR3 2380/4885DRD2 4124/4885OPRM1 1787/4885 |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | CCR3 974/4885DRD2 889/4885OPRM1 18/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | CCR3 974/4885DRD2 889/4885OPRM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.